Drug facts
MoleculeSacubitril and Valsartan (Entresto)
Generics already compete: 16 makers on the market. 48 A-rated products from 16 makers substitute at the counter.
Entresto was first approved by the FDA on 07/07/2015 under NDA 207620; the application holder is Novartis Pharmaceuticals Corp.
The latest NADAC for SACUBITRIL-VALSARTAN 49-51 MG is $0.54 per unit (as of 10/28/2026).
Holder Novartis Pharmaceuticals CorpApplication NDA 207620Approved 07/07/2015
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
3,478days until the latest Entresto patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved07/07/2015
Last patent05/09/2036
20162019202220252028203120342037
- Latest patent
- 05/09/2036Entresto Orange Book
- Later patents, other products
- Entresto Sprinkle 02/02/2037 Orange Book
02Competition
- Generics
- 16 generic makers Orange Book
- First generic approved
- 05/28/2024 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Sacubitril and Valsartan profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.54 per unitSACUBITRIL-VALSARTAN 49-51 MG, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Novartis Pharmaceuticals Corp Orange Book
- Application
- NDA 207620 Orange Book
- First approved
- 07/07/2015 Orange Book
- Dosage forms
- capsule, pellets; tablet
- Routes
- oral
- Other brand names
- Entresto Sprinkle
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.